Literature DB >> 6804223

The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers.

V Nitsche, H Mascher.   

Abstract

The pharmacokinetics of valproic acid were investigated in six healthy volunteers. After a single intravenous dose of 1,000 mg valproic acid, the pharmacokinetic parameters were determined according to the open two-compartment model. Bioavailability of valproic acid was performed comparing the areas under curves (AUC) after i.v and an equal single oral dose. The half-life of the initial phase was t 1/2 alpha = 0.64 +/- 0.32 h, and the elimination half-life was calculated as t 1/2 beta = 11.55 +/- 2.33 h. The distribution volume of the central compartment was Vc = 9.9 +/- 0.78 L, the apparent volume of distribution was Vd beta = 18.2 +/- 6.2 L, and the distribution volume at steady state was Vss = 12.6 +/- 1.2 L. The value for the average total clearance was Cltot = 51.1 +/- 11.9 ml/min. The study showed that in comparison to single dosing, the elimination half-life increased in average for four hours after multiple dosing (p less than or equal to 0.05). There was only a poor correlation between serum concentrations and concentration of valproic acid in saliva (r = 0.42).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6804223     DOI: 10.1111/j.1528-1157.1982.tb05063.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  9 in total

Review 1.  Therapeutic drug monitoring--antiepileptic drugs.

Authors:  M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

Review 2.  Feasibility of Using Oral Fluid for Therapeutic Drug Monitoring of Antiepileptic Drugs.

Authors:  Morgan Patrick; Samuel Parmiter; Sherif Hanafy Mahmoud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03       Impact factor: 2.441

Review 3.  Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 4.  Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants.

Authors:  H Liu; M R Delgado
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

5.  A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.

Authors:  Christelle Rodrigues; Stéphanie Chhun; Catherine Chiron; Olivier Dulac; Elisabeth Rey; Gérard Pons; Vincent Jullien
Journal:  Eur J Clin Pharmacol       Date:  2018-03-21       Impact factor: 2.953

Review 6.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

7.  Rectal administration of sodium valproate in children.

Authors:  E Scanabissi; D Dal Pozzo; E Franzoni; C Galloni; G Mengoli; R Calivà
Journal:  Ital J Neurol Sci       Date:  1984-06

Review 8.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

9.  Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex.

Authors:  Todd M Conner; Vahagn C Nikolian; Patrick E Georgoff; Manjunath P Pai; Hasan B Alam; Duxin Sun; Ronald C Reed; Tao Zhang
Journal:  Eur J Pharm Sci       Date:  2017-10-10       Impact factor: 4.384

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.